<code id='22647127C1'></code><style id='22647127C1'></style>
    • <acronym id='22647127C1'></acronym>
      <center id='22647127C1'><center id='22647127C1'><tfoot id='22647127C1'></tfoot></center><abbr id='22647127C1'><dir id='22647127C1'><tfoot id='22647127C1'></tfoot><noframes id='22647127C1'>

    • <optgroup id='22647127C1'><strike id='22647127C1'><sup id='22647127C1'></sup></strike><code id='22647127C1'></code></optgroup>
        1. <b id='22647127C1'><label id='22647127C1'><select id='22647127C1'><dt id='22647127C1'><span id='22647127C1'></span></dt></select></label></b><u id='22647127C1'></u>
          <i id='22647127C1'><strike id='22647127C1'><tt id='22647127C1'><pre id='22647127C1'></pre></tt></strike></i>

          hotspot

          hotspot

          author:entertainment    Page View:645
          Two researchers look at a projection screen displaying medical devices, scientific graphs and DNA — health tech coverage from STAT
          Adobe

          The federal government’s plan to boost its oversight of the use of artificial intelligence tools in health care drew censure from startups arguing that overregulation stifles new ideas. But as Washington forges ahead, founders say they’re in the dark about who will be regulated and how — and they’re urging policymakers to offer clarity.

          As they race for a slice of the $4 trillion U.S. health care market, AI founders and investors say regulatory uncertainty is a hurdle, forcing them to build more slowly and meticulously document for fear of potential audits. That makes it harder to keep up with the tech industry’s breakneck pace, they tell STAT.

          advertisement

          The regulatory uncertainty adds to the many challenges dogging young health tech ventures today: Last year investments in digital health startups shriveled to their lowest annual total since 2019, and leaders are desperate to preserve what little funds they have, including through layoffs.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Readout LOUD podcast: ALS dilemma, first MASH drug, and more
          Readout LOUD podcast: ALS dilemma, first MASH drug, and more

          Whathappenswhenanapproveddrugdoesn’twork?Whydon’tpatientswantgenetherapy?AndisMASHstillabigdeal?Weco

          read more
          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more

          Gene therapy’s promise and the high cost of hope

          AdobeAtthebustlingChicagoO’Hareairport,myluggageandIcollidedwithanelderlycouple.MyheartsankwhenIreal